JP2021036883A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021036883A5 JP2021036883A5 JP2020186004A JP2020186004A JP2021036883A5 JP 2021036883 A5 JP2021036883 A5 JP 2021036883A5 JP 2020186004 A JP2020186004 A JP 2020186004A JP 2020186004 A JP2020186004 A JP 2020186004A JP 2021036883 A5 JP2021036883 A5 JP 2021036883A5
- Authority
- JP
- Japan
- Prior art keywords
- car
- nucleic acid
- cells
- domain
- vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108020004707 nucleic acids Proteins 0.000 claims 9
- 102000039446 nucleic acids Human genes 0.000 claims 9
- 150000007523 nucleic acids Chemical class 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 8
- 239000000427 antigen Substances 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 230000001086 cytosolic effect Effects 0.000 claims 3
- 210000002865 immune cell Anatomy 0.000 claims 3
- 102000002467 interleukin receptors Human genes 0.000 claims 3
- 108010093036 interleukin receptors Proteins 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 102000010789 Interleukin-2 Receptors Human genes 0.000 claims 2
- 108010038453 Interleukin-2 Receptors Proteins 0.000 claims 2
- 102000004527 Interleukin-21 Receptors Human genes 0.000 claims 2
- 108010017411 Interleukin-21 Receptors Proteins 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 101001004391 Drosophila melanogaster Protein jim lovell Proteins 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 230000005809 anti-tumor immunity Effects 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 102000027411 intracellular receptors Human genes 0.000 claims 1
- 108091008582 intracellular receptors Proteins 0.000 claims 1
- 230000004068 intracellular signaling Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 108091006106 transcriptional activators Proteins 0.000 claims 1
- 230000002463 transducing effect Effects 0.000 claims 1
- 238000010361 transduction Methods 0.000 claims 1
- 230000026683 transduction Effects 0.000 claims 1
- 238000001890 transfection Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562115527P | 2015-02-12 | 2015-02-12 | |
| US62/115,527 | 2015-02-12 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017541919A Division JP6846352B2 (ja) | 2015-02-12 | 2016-02-11 | キメラ抗原受容体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021036883A JP2021036883A (ja) | 2021-03-11 |
| JP2021036883A5 true JP2021036883A5 (enExample) | 2021-10-28 |
Family
ID=56614021
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017541919A Active JP6846352B2 (ja) | 2015-02-12 | 2016-02-11 | キメラ抗原受容体 |
| JP2020186004A Pending JP2021036883A (ja) | 2015-02-12 | 2020-11-06 | キメラ抗原受容体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017541919A Active JP6846352B2 (ja) | 2015-02-12 | 2016-02-11 | キメラ抗原受容体 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US10336810B2 (enExample) |
| EP (1) | EP3256496B1 (enExample) |
| JP (2) | JP6846352B2 (enExample) |
| KR (1) | KR102607152B1 (enExample) |
| CA (1) | CA2974998C (enExample) |
| ES (1) | ES2857998T3 (enExample) |
| WO (1) | WO2016127257A1 (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016127257A1 (en) | 2015-02-12 | 2016-08-18 | University Health Network | Chimeric antigen receptors |
| EP3466967A1 (en) | 2015-05-18 | 2019-04-10 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| GB201518816D0 (en) | 2015-10-23 | 2015-12-09 | Autolus Ltd | Receptor |
| EP3458485B1 (en) * | 2016-05-19 | 2021-12-29 | The General Hospital Corporation | Tethered interleukin-2 to its receptor il-2rbeta, a platform to enhance natural killer and regulatory t cell activity |
| AU2017306432A1 (en) | 2016-08-02 | 2019-03-21 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
| JP7193862B2 (ja) | 2016-08-03 | 2022-12-21 | ワシントン・ユニバーシティ | キメラ抗原受容体でのｔ細胞性悪性腫瘍の治療のためのｃａｒ－ｔ細胞の遺伝子編集 |
| US20190119636A1 (en) | 2017-10-23 | 2019-04-25 | Poseida Therapeutics, Inc. | Modified stem cell memory t cells, methods of making and methods of using same |
| BR112019007100A2 (pt) | 2016-10-07 | 2019-06-25 | Tcr2 Therapeutics Inc | composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão |
| CA3044593A1 (en) | 2016-11-22 | 2018-05-31 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| JP7206214B2 (ja) | 2016-12-13 | 2023-01-17 | シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） | インビトロ及びインビボで操作された細胞において発現された化学誘導シグナル伝達複合体の外因性薬物活性化の方法 |
| MX2020009051A (es) * | 2018-03-02 | 2020-12-03 | Allogene Therapeutics Inc | Receptores de citocina quimericos inducibles. |
| WO2019175328A1 (en) | 2018-03-14 | 2019-09-19 | Imba - Institut Für Molekulare Biotechnologie Gmbh | Bh4pathwayactivationandusethereoffortreatingcancer |
| KR20210005922A (ko) * | 2018-04-27 | 2021-01-15 | 크리스퍼 테라퓨틱스 아게 | 형질 세포 고갈을 위한 항-bcma car-t-세포 |
| CA3091490A1 (en) | 2018-04-27 | 2019-10-31 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Rapamycin resistant cells |
| CN110615843B (zh) * | 2018-06-20 | 2023-05-09 | 上海隆耀生物科技有限公司 | 一种包含第三信号受体的嵌合抗原受体及其应用 |
| GB201814203D0 (en) * | 2018-08-31 | 2018-10-17 | King S College London | Engineered regulatory t cell |
| AU2019336031B2 (en) * | 2018-09-05 | 2024-07-11 | Act Therapeutics Inc. | Chimeric antigen receptor for solid cancer and T cells expressing chimeric antigen receptor |
| AU2020224160A1 (en) * | 2019-02-21 | 2021-08-26 | John M. LUK | Artificial immunosurveillance chimeric antigen receptor (AI-CAR) and cells expressing the same |
| JP7633937B2 (ja) | 2019-03-01 | 2025-02-20 | アロジーン セラピューティクス，インコーポレイテッド | Ｐｄ－１外部ドメインを担持するキメラサイトカイン受容体 |
| JP7667086B2 (ja) | 2019-03-01 | 2025-04-22 | アロジーン セラピューティクス，インコーポレイテッド | 構成的に活性なキメラサイトカイン受容体 |
| GB201911187D0 (en) * | 2019-08-05 | 2019-09-18 | Autolus Ltd | Receptor |
| GB201912515D0 (en) * | 2019-08-30 | 2019-10-16 | King S College London | Engineered regulatory T cell |
| CN114761424B (zh) * | 2019-09-05 | 2025-09-19 | 波赛达治疗公司 | 同种异体细胞组合物和使用方法 |
| CN110717956B (zh) * | 2019-09-30 | 2023-06-20 | 重庆大学 | 一种有限角投影超像素引导的l0范数最优化重建方法 |
| TWI717880B (zh) * | 2019-10-24 | 2021-02-01 | 中國醫藥大學附設醫院 | Hla-g特異性嵌合抗原受體、核酸、hla-g特異性嵌合抗原受體表達質體、表達hla-g特異性嵌合抗原受體細胞、其用途以及用於治療癌症之醫藥組合物 |
| KR20220131529A (ko) * | 2020-01-14 | 2022-09-28 | 신테카인, 인크. | 변경된 icd stat 신호전달을 갖는 cd122 |
| WO2021146487A2 (en) * | 2020-01-14 | 2021-07-22 | Synthekine, Inc. | Il2 orthologs and methods of use |
| CN115175929A (zh) | 2020-02-24 | 2022-10-11 | 艾洛基治疗公司 | 活性增强的bcma car-t细胞 |
| GB2609103A (en) * | 2020-02-25 | 2023-01-25 | Quell Therapeutics Ltd | Chimeric receptors for use in engineered cells |
| WO2021183795A1 (en) * | 2020-03-11 | 2021-09-16 | Poseida Therapeutics, Inc. | Chimeric stimulatory receptors and methods of use in t cell activation and differentiation |
| IL298279A (en) * | 2020-04-17 | 2023-01-01 | Council Queensland Inst Medical Res | Immune cells with enhanced function |
| EP4139345A1 (en) * | 2020-04-24 | 2023-03-01 | Sorrento Therapeutics, Inc. | Memory dimeric antigen receptors |
| KR102297396B1 (ko) | 2020-07-29 | 2021-09-06 | (주)티카로스 | 면역시냅스를 안정화시키는 키메라 항원 수용체(car) t 세포 |
| US12012441B2 (en) | 2020-10-26 | 2024-06-18 | Neptune Biosciences Llc | Engineered human IL-21 cytokines and methods for using the same |
| US20250270320A1 (en) | 2020-12-10 | 2025-08-28 | Eutilex Co., Ltd. | Anti-pd-1 antibody and uses thereof |
| CN114716548B (zh) | 2021-01-05 | 2024-11-05 | (株)爱恩德生物 | 抗-fgfr3抗体及其用途 |
| CN113512125B (zh) * | 2021-04-26 | 2024-01-19 | 北京双赢科创生物科技有限公司 | 一种携带stat结合基序的嵌合抗原受体分子及表达该嵌合抗原受体分子的nk细胞 |
| US12202884B2 (en) | 2021-09-17 | 2025-01-21 | Parker Institute For Cancer Immunotherapy | Nucleic acids encoding switch receptors using IL-9 receptor signaling domains |
| WO2023158997A2 (en) * | 2022-02-15 | 2023-08-24 | Memorial Sloan-Kettering Cancer Center | Compositions including killer innate-like t cells and uses therof |
| WO2023159000A2 (en) * | 2022-02-15 | 2023-08-24 | Memorial Sloan-Kettering Cancer Center | Compositions including cytotoxic innate lymphoid cells and uses therof |
| US20250319131A1 (en) * | 2022-07-11 | 2025-10-16 | The Board Of Trustees Of The Leland Stanford Junior University | Tunable cytokine receptor signaling domains |
| AU2023313641A1 (en) | 2022-07-26 | 2025-03-13 | Aimed Bio Inc. | Anti-ror1 antibody and use thereof |
| EP4342907A1 (en) | 2022-09-21 | 2024-03-27 | AvenCell Europe GmbH | Switchable chimeric antigen receptors and their use |
| IL319598A (en) | 2022-09-30 | 2025-05-01 | Caribou Biosciences Inc | Anti-ROR1 chimeric antigen receptors, CAR-NK cells and related methods |
| EP4633648A1 (en) * | 2022-12-15 | 2025-10-22 | Carisma Therapeutics Inc. | Chimeric antigen receptors including jak/stat binding domains and modified immune cells |
| WO2025096673A1 (en) * | 2023-10-30 | 2025-05-08 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions comprising cells targeting cancer and methods of using the same |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4694778A (en) | 1984-05-04 | 1987-09-22 | Anicon, Inc. | Chemical vapor deposition wafer boat |
| US5837544A (en) * | 1995-02-02 | 1998-11-17 | Cell Genesys, Inc. | Method of inducing a cell to proliferate using a chimeric receptor comprising janus kinase |
| US20130266551A1 (en) | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
| EP1795599A1 (en) | 2005-12-09 | 2007-06-13 | Schuler, Gerold, Prof. Dr. | Methods for generating antigen-specific effector T cells |
| WO2008042814A2 (en) | 2006-09-29 | 2008-04-10 | California Institute Of Technology | Mart-1 t cell receptors |
| US9409969B2 (en) | 2009-02-09 | 2016-08-09 | Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) | Repertoire of allo-restricted peptide-specific T cell receptor sequences and use thereof |
| WO2012154858A1 (en) | 2011-05-09 | 2012-11-15 | Whitehead Institute For Biomedical Research | Chaperone interaction assays and uses thereof |
| AU2013204922B2 (en) * | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
| ES2828982T3 (es) * | 2013-05-14 | 2021-05-28 | Univ Texas | Aplicación humana de células t de receptor de antígeno quimérico (car) diseñadas |
| WO2014190273A1 (en) * | 2013-05-24 | 2014-11-27 | Board Of Regents, The University Of Texas System | Chimeric antigen receptor-targeting monoclonal antibodies |
| WO2016127257A1 (en) | 2015-02-12 | 2016-08-18 | University Health Network | Chimeric antigen receptors |
-
2016
- 2016-02-11 WO PCT/CA2016/050126 patent/WO2016127257A1/en not_active Ceased
- 2016-02-11 CA CA2974998A patent/CA2974998C/en active Active
- 2016-02-11 US US15/550,645 patent/US10336810B2/en active Active
- 2016-02-11 EP EP16748518.4A patent/EP3256496B1/en active Active
- 2016-02-11 ES ES16748518T patent/ES2857998T3/es active Active
- 2016-02-11 JP JP2017541919A patent/JP6846352B2/ja active Active
- 2016-02-11 KR KR1020177025120A patent/KR102607152B1/ko active Active
-
2019
- 2019-05-14 US US16/411,941 patent/US10822392B2/en active Active
-
2020
- 2020-11-06 JP JP2020186004A patent/JP2021036883A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021036883A5 (enExample) | ||
| JP6983909B2 (ja) | ヒト化標的化ドメインを有するｒｏｒ１特異的キメラ抗原受容体（ｃａｒ） | |
| JP2024138280A5 (enExample) | ||
| Cohen et al. | Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability | |
| JP2022164858A (ja) | 免疫調整性ｉｌ２ｒ融合タンパク質およびその使用 | |
| JP2022109953A5 (enExample) | ||
| JP2019176869A5 (enExample) | ||
| US11591613B2 (en) | Retroviral and lentiviral vectors | |
| JP2016538855A5 (enExample) | ||
| JP2018523484A5 (enExample) | ||
| JP2021500894A (ja) | キメラ抗原受容体発現細胞を作製する方法 | |
| TW202000691A (zh) | 嵌合跨膜蛋白及其用途 | |
| JP2019517267A5 (enExample) | ||
| JP2017515464A5 (enExample) | ||
| US11299552B2 (en) | Eliminating MHC restriction from the T cell receptor as a strategy for immunotherapy | |
| KR20140127816A (ko) | 암의 치료에 유용한 t 세포의 지속성 집단을 생성시키기 위한 조성물 및 방법 | |
| JP2021536240A (ja) | 改良された治療用ｔ細胞 | |
| Rubinstein et al. | Transfer of TCR genes into mature T cells is accompanied by the maintenance of parental T cell avidity | |
| Matsuzaki et al. | A rare population of tumor antigen-specific CD4+ CD8+ double-positive αβ T lymphocytes uniquely provide CD8-independent TCR genes for engineering therapeutic T cells | |
| JP2021516049A (ja) | 組換えｔ細胞受容体遺伝子を用いて細胞ベースの治療薬を製造するための技法 | |
| JP7466231B2 (ja) | キメラ抗原受容体及びその適用 | |
| Yoshida et al. | A novel adenovirus expressing human 4–1BB ligand enhances antitumor immunity | |
| JP2015223143A (ja) | Ｔｃｒの細胞傷害活性誘導能を評価するためのｎｋ細胞株、およびその作製方法 | |
| WO2024193714A1 (zh) | 细胞免疫疗法的组合物和方法 | |
| CN119301150A (zh) | 人工免疫受体 |